氯吡格雷用于急性非致残性脑血管高危患者的临床研究

Clinical Studies of Clopidogrel for Acute Non-disabling Cerebral Vascular Risk Patients

目的：探讨氯吡格雷用于急性非致残性脑血管高危患者的临床价值及用药安全性。方法选取2012年12月～2014年1月我院收治的短暂性脑缺血发作（TIA）和急性缺血性小卒中患者80例，按数字法随机分为对照组与观察组各40例。对照组给予单纯阿司匹林治疗，观察组采取阿司匹林加氯吡格雷联合用药，比较两组患者的临床效果及不良反应发生情况。结果观察组总有效率与对照组相比，差异有统计学意义（P<0.05）；两组患者胃肠道反应、皮肤黏膜出血、皮疹及白细胞减少等不良反应发生率差异无统计学意义（P>0.05）。结论氯吡格雷联合阿司匹林治疗急性非致残性脑血管高危患者的临床疗效显著，明显优于单纯阿司匹林治疗，且可保证用药安全性，值得临床推广使用。

Objective To investigate the clinical value and safety of clopidogrel in the treatment of a-cute non-disabling cerebral vascular risk patients. Methods 80 patients with transient ischemic attack (TIA) and minor stroke in our hospital from December 2012 to January 2014 were selected as sub-jects. According to figures randomly, all subjects were divided into control group and observation group, each group with 40 cases. The control group was received aspirin alone, aspirin and clopidogrel were received in observation group. The clinical results of the two groups and the incidence of adverse reac-tions were compared. Results The total effective rate was observed and compared, the difference was statistically significant (P<0.05). Incidence of gastrointestinal reactions, skin and mucous membrane bleeding, rash and leukopenia were no significant difference (P>0.05). Conclusion The clinical effi-cacy of clopidogrel and aspirin in the treatment of acute non-disabling cerebral vascular risk patients is significant, significantly better than aspirin. It can ensure safety, be worthy of clinical application.